DGIjx_WWAAAS7cl.jpg

Medicrea Reports Third Quarter 2017 Sales

Posted On October 13, 2017 By OrthoSpineNews In Financial /  

October 12, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, publishes its sales for the 3rd quarter ended September 30, 2017.

€ millions 2016 2017 Change

Q3

6.8

6.4

-5%
9 months to September 30 21.6 21.1 -2%

Changes in foreign exchange rates had no material impact on sales for the period

Sales totaled €6.4 million over the 3rd quarter, down 5% compared to the same period of 2016, adversely affected since the start of the fiscal year by the complete lack of commercial activity in Brazil (the leading export market up to that point, excluding the distribution subsidiaries) since the beginning of the year.

The regulatory certifications required to deliver the Medicrea implants, now fully manufactured in the new ultra-modern Lyon facilities, to the Brazilian market have been definitively obtained since the ANVISA audit, which confirmed the compliance of the equipment and soundness of the Company’s quality system. This inability to deliver to the Brazilian market since the beginning of 2017 will generate a sales shortfall of almost €2 million over the full year 2017. Sales in Brazil will return to a normative level in 2018. In the United States, the momentum for adoption of UNiD™ ASI technology continues with the implantation of patient-specific UNiD™ Rods posting growth in excess of 42% over the 9 months to September 30, 2017 compared to the same period of 2016.

“Our development model is transforming, with the gradual integration of a unique and comprehensive digital healthcare platform that no other traditional spinal implant manufacturer is able to offer today. In the United States, this transformation was accompanied by organizational changes and a necessary adaptation of the sales force, more accustomed to selling surgical implants than offering sophisticated planning services and personalized solutions with high added value for each patient and adapted to the technique of each surgeon. The overall growth of our activity in this priority market is temporarily affected by these changes, but I am confident that with the two major recruitments we have just achieved, which we will be announcing in the near future, and especially with the very promising clinical results recently released with the publication of our White Paper on rod fracture rates, the use of our UNID™ ASI technology by surgeons and hospitals should accelerate significantly,” stated Denys Sournac, President and CEO of Medicrea.

Next publication: 2017 Annual Sales on January 11, 2018 after market.

About Medicrea (www.Medicrea.com)

Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of patient-specific implants 3D-printed from powdered Titanium.

For further information, please visit: Medicrea.com.

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED
LEI: 969500BR1CPTYMTJBA37

Contacts

Medicrea
Denys Sournac
Founder, Chairman and CEO
dsournac@Medicrea.com
or
Fabrice Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@Medicrea.com

Read More

OrthoPediatrics Corp. (Nasdaq: KIDS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO

Posted On October 13, 2017 By OrthoSpineNews In Financial /  

ADVISORY, Oct. 13, 2017 (GLOBE NEWSWIRE)

What:
OrthoPediatrics Corp. (Nasdaq:KIDS), the only orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) on October 12, 2017.

In honor of the occasion, Mark Throdahl, President & Chief Executive Officer, will ring the Opening Bell.

Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:
Friday, October 13, 2017 – 9:15 a.m. to 9:30 a.m. ET

OrthoPediatrics Corp. Media Contact:
Zack Kubow, The Ruth Group
646-536-7020
zkubow@theruthgroup.com

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About OrthoPediatrics Corp
Founded in 2006, OrthoPediatrics is the only orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 21 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products to 35 countries outside the United States.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQA-

Read More
index.6jpg-lightbox.jpg

EOS imaging Reports 28% Sales Growth for the Third Quarter 2017

Posted On October 12, 2017 By OrthoSpineNews In Financial /  

October 12, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – SME), the pioneer of orthopaedic medical imaging, 2D/3D, today announced its (non-audited) consolidated sales for the third quarter ended September 30, 2017. The Company also announced the appointment of Eric Maulavé as Chief Operating Officer (COO) as part of its ongoing effort to develop its leadership team, and highlighted its participation at the Journées Francophones de Radiologie (JFR) meeting, which will take place from October 12 – 16, 2017 in Paris.

Marie Meynadier, Chief Executive Officer of EOS imaging, commented: “Sales in the third quarter grew 28%, reflecting strong performance in Europe and the stabilization of our North American business, which is beginning to benefit from new leadership and organizational structure. During the quarter we also had good growth in our recurring sales categories driven by our expanding installed base. Looking forward, we are confident that our North American team is building momentum that should bring a return to sustained growth in the region at the end of the year. We are also pleased to appoint Eric Maulavé to the new position of Chief Operating Officer, with responsibility for operations outside of North America. This is a natural expansion of the team to support our growth worldwide. Finally, our investments in developing new software applications continue to build the value of the EOS platform and we look forward to presenting our new connectivity solution at the JFR meeting, which is the largest radiology meeting in France.”

Third Quarter Sales by Product Line
€ millions Q3 2017 Q3 2016 variation
Equipment Sales 6,74 5,47 +23%
Sales of Maintenance 1,47 0,96 +52%
Sales of consumables and services 0,25 0,19 +39%
Total Sales 8,46 6,61 +28%

(unaudited)

In the third quarter of 2017, the Company generated revenue of €8.5 million, up 28% compared to the third quarter of 2016. The Company sold 17 EOS® systems during the third quarter of 2017, compared to 13 systems in the same period last year. Sales of maintenance contracts increased by 52% to €1.5 million, reflecting the continued growth of the installed base of EOS systems under contract. Recurring revenue in the third quarter of 2017 represented 20% of total sales, compared to 17% of total sales in the same period last year.

Third Quarter Sales by Geography
€ millions Q3 2017 Q3 2016 variation
EMEA 4,13 1,95

+111%
As % of total sales 49% 30%
North America 3,44 3,91

-12%
As % of total sales 41% 59%
Asia-Pacific 0,89 0,75

+19%
As % of total sales 11% 11%
Total Sales 8,46 6,61 +28%

(unaudited)

The increase in revenues over the third quarter of 2017 was mainly driven by strong sales in Europe. In North America, sales declined but were trending toward more stable results as the Company begins to benefit from new leadership and organizational structure.

Nine Month 2017 Sales by Product Line
€ millions September 30, 2017 September 30, 2016 variation
Equipment Sales 19,89 16,93

+18%
As % of total sales 80% 82%
Sales of Maintenance 4,29 3,18

+35%
As % of total sales 17% 15%
Sales of consumables and services 0,74 0,65

+15%
As % of total sales 3% 3%
Total Sales 24,93 20,75 +20%

(unaudited)

Nine Month 2017 Sales by Geography
€ millions September 30, 2017 September 30, 2016 variation
EMEA 11,52 7,27

+58%
As % of total sales 46% 35%
North America 9,18 11,57

-21%
As % of total sales 37% 56%
Asia-Pacific 4,23 1,92

+121%
As % of total sales 17% 9%
Total Sales 24,93 20,75 +20%

(unaudited)

In the first nine months of 2017, the Company sold 51 EOS® systems, compared to 41 systems in the same period last year.

Quarterly sales trend, by Product Line
Q1

2017

 Q2

2017

 Q3

2017

 Q1

2016

 Q2

2016

 Q3

2016

 ΔQ1 ΔQ2 ΔQ3
Equipment Sales 5,47 7,67 6,76 4,09 7,36 5,46 +34% +4% +23%

Sales of Maintenance

 1,40 1,43 1,46 0,99 1,23 0,96 +41% +16% +52%
Other Sales 0,26 0,23 0,25 0,24 0,22 0,19 +9% +3% +39%
Total Sales 7,13 9,34 8,46 5,33 8,82 6,61 +34% +6% +28%

(unaudited)
  • Appointment of Eric Maulavé to the Position of Chief Operating Officer

As part of the continued execution of its global growth strategy, the Company is strengthening its senior leadership with the appointment of Eric Maulavé as Chief Operating Officer effective October 1, 2017. In this position Eric will have responsibility for production, maintenance, engineering, clinical, quality/regulatory activities as well as sales in the EMEA, Asia-Pacific and LATAM regions. Mr. Maulavé previously served as the Company’s Vice President of Global Sales and has been with the Company since 2012.

  • Journées Francophones de Radiologie

The company will present its new 3D image sharing application at the Journées Francophones de Radiologie (JFR) meeting in Paris from October 12-16, 2017, focused this year on the patient. The new software is dedicated to 2D/3D and clinical data sharing and aimed at facilitating the relationship between radiologist, patient and referring physician (orthopedic surgeon, rheumatologist or general practitioner).

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging service dedicated to osteo-articular pathologies and orthopaedics, as well as the associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan, and the European Union (EC). It posted revenues of €30.8 million in 2016 and employed 132 people at December 2016, including an R&D team of 43 engineers. The group is based in Paris and has five subsidiaries: in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

EOS imaging has been selected to integrate the EnterNext © PEA – SME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Pierre Schwich, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent, +33 (0)1 44 71 94 96
eosimaging@newcap.eu
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com

Read More
AVANZA_57891-1.jpg

Exactech Comments on Impact of Hurricanes Irma and Harvey; Adjusts Q3 Earnings Guidance and Announces Q3 Earnings Call

Posted On October 12, 2017 By OrthoSpineNews In Financial /  

October 12, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, said today it is adjusting guidance for the third quarter of 2017 as a result of the impact of Hurricanes Irma and Harvey.

CEO and President David Petty said the estimated US revenue impact of the two hurricanes was approximately $1.2M to sales in Q3 across Florida, Texas, Georgia and the Carolinas.

“We were fortunate that our facilities were undamaged during the hurricanes. However, the storms caused our surgeon customers in the affected states to postpone scheduled surgeries, directly affecting our Q3 revenue stream. In addition, due to hurricane preparation procedures at our Gainesville and Sarasota locations, our manufacturing and shipping operations lost two days of operating capacity. As a result, domestic revenues were near the bottom of our expectations. We now expect to report approximately $61.4MM in worldwide revenue for the third quarter. We also are adjusting our EPS guidance for the quarter to $0.19-$0.21 per share, a reduction of approximately $0.04 per share from our previously issued guidance of $0.23-$0.25 per share due to the net income impact of these lower revenues as well as the impact of the operations interruption,” Petty said.

The company will release its third quarter 2017 financial results on Monday, October 30, 2017. A copy of the earnings release will be available at http://www.hawkassociates.com.

The company will host a conference call with CEO David Petty and key members of the management team on Tuesday, October 31 at 10:00 a.m. Eastern Time. The call will cover Exactech’s third quarter 2017 results. Mr. Petty will open the conference call and a question-and-answer session will follow.

To participate in the call, dial 1-800-334-0872 any time after 9:50 a.m. Eastern on October 31. International and local callers should dial 1-719-325-4845. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm or http://public.viavid.com/index.php?id=126701. This call will be archived for approximately 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Contacts

Exactech, Inc.
Investor contacts
Jody Phillips, 352-377-1140
Executive Vice President of Finance &
Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
EXAC@hawkassociates.com
or
Media contact
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

Read More
Corporate_video_building_788x335.jpg

Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25

Posted On October 11, 2017 By OrthoSpineNews In Financial /  

October 11, 2017

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the “Investor Relations” section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®,which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®,a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, Chief Financial Officer
Tel: 781.457.9000
or
For Media Inquiries:
Pure Communications
Sonal Vasudev
Tel: 917.523.1418

Read More
NASDAQ_WMGI-1.png

Wright Medical Group N.V. to Host Third Quarter 2017 Earnings Conference Call

Posted On October 11, 2017 By OrthoSpineNews In Financial /  

AMSTERDAM, The Netherlands, Oct. 11, 2017 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will host a conference call on Wednesday, November 1, 2017, at 3:30 p.m. Central Time to discuss the company’s operating results for its third quarter ended September 24, 2017.  Operating results will be released at 3:00 p.m. Central Time that day.

The live dial-in number for the call is (844) 295-9436 (U.S.) / (574) 990-1040 (Outside U.S.).  The participant passcode for the call is “Wright.”  A simultaneous webcast of the call will be available via Wright Medical’s corporate website at www.wright.com.  The call will be archived on this site for a minimum of 12 months.

A replay of the call will be available beginning at 5:30 p.m. Central Time on November 1, 2017 through November 8, 2017.  To hear this replay, dial (855) 859-2056 (U.S.) / (404) 537-3406 (Outside U.S.) and enter code 65776375.

Internet Posting of Information

Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com.  The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.

About Wright Medical Group N.V.

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products.  The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide.  Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopedics.  For more information about Wright, visit www.wright.com.

Investors & Media:

Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
julie.tracy@wright.com

Primary Logo

Wright Medical Group N.V.

Read More

Implanet: 20% Increase in Revenue In Q3 2017

Posted On October 10, 2017 By OrthoSpineNews In Financial /  

October 10, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its sales for the third quarter and first nine months to September 30, 2017.

Ludovic Lastennet, CEO of Implanet, says: “The Group’s activity was solid last quarter. The increase in Jazz® sales in Q3 2017 represented the best quarterly improvement since the start of the year, confirming the success of the Jazz® technological platform’s expansion across all of our territories. France and the Rest of the World are continuing to grow. In the United States, our efforts about getting Jazz®’s clinical value acknowledged and recruiting and training partners of greater size are beginning to bear fruit. These encouraging results illustrate our ability to generate sustained growth in Jazz® revenue quarter after quarter.”

Revenue (in € thousands – IFRS*) 2017 2016 Change
1st quarter 2,048 1,988 +3%
2nd quarter 2,071 2,107 -2%
Spine (JAZZ) 1,104 848 +30%
Knee + Arthroscopy 671 633 +6%
Total 3rd quarter 1,774 1,481 +20%
Spine (JAZZ) 3,506 2,860 +23%
Knee + Arthroscopy 2,387 2,715 -12%
9-month revenue 5,894 5,576 +6%

*Unaudited data

Sales in the first 9 months were up 6% to €5.9 million (from €5.6 million), confirming the successful deployment of Jazz® technology across all regions.

Jazz® sales recorded growth of 30% to €1.1 million in Q3 2017, the strongest quarterly growth since the start of the year. Over the first nine months of 2017, Jazz® sales were up by 23% (close to 60% of total revenue vs. 51% in 2016).

Jazz® sales were up in every region over the quarter: 10% to €0.3 million in France and 159% to €0.3 million in the rest of the world. Over the first nine months of the year, Jazz® sales were up 20% to €1.1 million in France and by 117% to €0.8 million in the rest of the world.

In the rest of the world, the performance was driven by longstanding distributors and by Jazz® launch in new European countries.

In the United States, Jazz® sales were up 12% (16% at constant currency) to €0.5 million in Q3. The strategy of partnering with larger players is beginning to bear fruit, enabling us to accelerate the recruitment of new surgeons.

On markets where the Company operates directly, i.e. France and the United States, the penetration of the adult degenerative bone disorder market – which is acyclic and has substantial potential – keeps growing; sales were up 5% to €0.3 million over the quarter. Pediatric activity also increased 20% over the quarter to €0.5 million.

In the quarter, Implanet sold 1,655 Jazz® units (vs. 1,505 in Q3 2016). Over the first nine months of the year, Implanet thus sold a total of 6,296 units (vs. 4,623 in 2016).

As anticipated, the Knee segment saw sales stabilize with growth of 6% to €0.7 million in the third quarter, the gradual discontinuation of the distribution of arthroscopy activity having been completed. Sales of the proprietary product Madison (knee prosthesis) were flat on the first nine months of the year.

IMPLANET will participate in the following Scientific Congress in Q4 2017:
NASS in Orlando, October 25 to 28, 2017
SOFCOT in Paris, November 6 to 9, 2017

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Euronext™ Growth market in Paris.

Disclaimer
This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba
Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen
Tel.: +1 917 385 21 60
implanet@alphabronze.net

Read More
mimedx.png

MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent

Posted On October 10, 2017 By OrthoSpineNews In Financial /  

MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its preliminary revenue results for the third quarter of 2017.

Third Quarter 2017 Revenue Highlights 

  • Q3 2017 revenue of $84.6 million exceeded MiMedx guidance range of $79 to $80 million 
  • Q3 2017 revenue grew 31% over Q3 2016 revenue
  • First nine months of 2017 revenue grew 33% over first nine months of 2016
  • Distributor and OEM revenue was below 5%
  • Accounts receivable DSO down to mid-60s

The Company recorded record revenue for the 2017 third quarter of $84.6 million, a $20.2 million or 31% increase over 2016 third quarter revenue of $64.4 million. Revenue for the nine months ended September 30, 2017 was $233.6 million, a $58.5 million or 33% increase over revenue for the nine months ended September 30, 2016 of $175.1 million.

Parker H. “Pete” Petit, Chairman and CEO stated, “Our third quarter revenue performance was very strong, and we are very pleased with the robust momentum that our sales organization is building. It became evident to us in early September that this momentum would produce third quarter revenue in excess of our earlier expectations. Despite the disruption from Hurricane Harvey and Hurricane Irma, we were confident that our strong performance throughout the country would more than make up for the impact of these natural disasters. We are particularly pleased with the exceptionally strong revenue performance from our commercial accounts. Over the years, we have concentrated on developing a customer base with a very wide breadth, both geographically and functionally. We are extremely pleased with the span of the customer base that we have built now in ‘secondary markets’. Revenue from our commercial accounts is leading our robust growth. Revenue from our direct sales force is currently in excess of 95% of our total revenue with revenue from distributors and Original Equipment Manufacturer (OEM) accounts below 5% of our total revenue.”

Speaking to other aspects of third quarter performance, Petit added, “We had very strong cash flow from operations and expect to report continued progress in our Days Sales Outstanding (DSO). We anticipate that our DSO as of the end of the third quarter will be improved into the mid-60s. I would have to state that our other operations are also working quite efficiently. These financial metrics indicate that our shipped products are being utilized by our customers at an efficient rate.”

Bill Taylor, President and COO, said, “Our revenue performance for the third quarter marks 27 consecutive quarters of sequential revenue growth and 26 of the last 27 quarters of meeting or exceeding our revenue guidance. We are gratified to have exceeded our guidance by more than $4 million. The asset base we have built in our sales force and other critical functions of our organization are performing very effectively. Throughout the organization, the enthusiasm for our excellent potential in the biopharma market is very high, and this is being reflected in the momentum our sales force is building in the market place. We could not be more pleased with the results our organization is producing and the respect we have garnered in the market.”

Taylor continued, “During the quarter, we announced the results of a number of clinical studies that should be important catalysts in driving revenue performance in various applications. With the momentum our sales force has built and these types of compelling study results, we are looking forward to continuing our robust sales growth. It is also important to mention that we had a number of our sales force and their customers heavily impacted by the natural disasters that occurred during the quarter. I am especially proud of how the members of the sales team in the affected areas, who endured the impact of these disasters, and yet gave so much support to their customers to get their patients the care they needed.”

Petit noted, “Adding to the effectiveness and results our sales force is generating are the many sales efficiencies we have implemented. Our Sales Management System (SMS) and advanced territory analytics have made solid contributions to our growth capabilities. We have been highly successful in our market expansion initiatives, one of which is our strategy to dedicate resources in ‘secondary markets’. Our sales force has now grown to the size that we are working very efficiently in the ‘secondary markets’. Utilizing our SMS and territory management capabilities, we have been pleased with our success in opening these secondary markets and gaining incremental revenue.”

“We are going through the natural maturation processes that well-run businesses achieve at various stages in their growth. Combined with our exceptional product offerings, this maturation should continue to produce an impressive growth trajectory,” added Taylor.

“We believe our sales organization will continue to produce robust revenue growth, and we should continue our trend of exceeding expectations. We look forward to discussing with our shareholders later this month many other positive details along with our full third quarter results,” concluded Petit.

Dates for Release of Third Quarter 2017 Results and Two Live Broadcast Conference Calls
The Company also announced today that it plans to release its full results for the third quarter ended September 30, 2017, before the opening of the market on Friday, October 27, 2017. The Company also announced that it will provide revenue guidance for the fourth quarter of 2017 in that quarterly earnings release.

MiMedx will host its standard live broadcast of the Company’s third quarter conference call on Friday, October 27, 2017at 10:30 a.m. eastern time. A listen-only simulcast of the MiMedx conference call will be available online at the Company’s website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company’s website at www.mimedx.com.

Please note that MiMedx will host a live broadcast of a conference call this Wednesday, October 11, 2017 at 10:30 a.m. eastern time to discuss the topics included in this press release. A listen-only simulcast of the MiMedx conference call will be available online at the Company’s website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company’s website at www.mimedx.com.

About MiMedx
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary Statement
This press release includes forward-looking statements, including statements regarding sales momentum, future revenues, the future level of days sales outstanding, and the potential contribution of pending clinical studies. These statements also may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that the actual third quarter of 2017 final revenue number may differ from the preliminary number, the results of clinical studies may be delayed or below expectations; that sales momentum and revenue growth may moderate; and that days sales outstanding may increase. For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com

Read More
DS3_3612a.jpg

MiMedx Board of Directors Authorizes $10 Million Increase to the Company’s Share Repurchase Program

Posted On October 10, 2017 By OrthoSpineNews In Financial /  

MARIETTA, Ga., Oct. 9, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the decision of its Board of Directors to authorize a $10 million increase in the Company’s Share Repurchase Program.

This action by the MiMedx Board of Directors authorizing the additional $10 million to the Company’s Share Repurchase Program brings the total authorized to $110 million since the Share Repurchase Program commenced in May 2014. The Company reported that in light of the short seller attacks and its strong balance sheet and cash flows, the MiMedx Board of Directors believes the stock repurchases continue to be an extremely positive investment for MiMedx.  The Board also agreed to review this program again at its scheduled meeting on October 26, 2017, and to consider an additional commitment at that time.

Parker H. “Pete” Petit, Chairman and CEO, stated, “To date, we have utilized virtually all of the $100 million previously authorized by the Board. This program has been particularly beneficial for the Company, as we have acquired shares at very low prices for a company with our level of sustained growth, biopharma strategy, outstanding clinical trials, the consistent pattern of physician and payer reception in the market place and our robust pipeline of future products. The recent deceptive and contrived attacks on our stock have caused the MiMedx shares to become very undervalued in my opinion. I believe it is a very prudent use of our capital to acquire our shares at this point, and our high growth profile in both revenues and profits should produce an extremely anti-dilutive result from our stock repurchases.”

“We share the frustration from the short selling activity with all of our shareholders, and we are aggressively pursuing avenues that will expose these illegal activities,” concluded Petit.

About MiMedx

MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.   MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary Statement

This press release includes forward-looking statements, including statements regarding the Company’s stock repurchases are a positive investment for the Company and a prudent use of the Company’s capital, the belief that the Company’s stock price is very undervalued at present,  the Company’s expectations to continue the use of the share repurchase program to enhance shareholder value.  These statements also may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements.  Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the stock repurchases may not be a positive investment or a prudent use of the Company’s capital, the Board may not consider a substantial new commitment to the share repurchase program at its October 26, 2017 meeting, the Company’s stock price may not be undervalued, the Company’s continued use of the share repurchase program may not enhance shareholder value or the Company may not continue to use the share repurchase program.  For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission.  Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com

Read More
mazor-spine-surgery-st-francis-hospital-memphis.jpg

Mazor Robotics Received 22 System Orders During Q3 2017; Expects to Report Record Quarterly Revenue

Posted On October 9, 2017 By OrthoSpineNews In Financial, Robotics /  

October 09, 2017

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical robotic systems, expects to report record revenue of approximately $17.2 million for the third quarter ended September 30, 2017. During the third quarter of 2017, the Company received a total of 22 system purchase orders from customers in the U.S., Asia and Israel. The 22 orders are comprised of:

  • 19 purchase orders for the Mazor X™ system, of which 11 were ordered by Medtronic. As of September 18, 2017, Medtronic assumed full responsibility for the distribution of the Mazor X system, as part of the second phase of the commercial agreement between the companies. Five of the Medtronic ordered systems were delivered in Q3.
  • A purchase order for three Renaissance systems from the Company’s distribution partner in China, one of which was delivered in Q3.

“This quarter we transferred to Medtronic members of our talented capital sales team along with a solid sales pipeline. This transition was performed in a smooth and effective manner and we maintained robust sales activity during the transition period,” commented Ori Hadomi, Chief Executive Officer. “The continued strong performance in the third quarter of 2017 reflects the increased demand and interest in Mazor’s robotic platforms.”

Mazor’s system backlog at the end of the third quarter was 17 systems (15 Mazor X and two Renaissance systems). The Company intends to report its financial results for the third quarter ended September 30, 2017 on or about November 7, 2017 and will issue a press release with the specific time, dial-in credentials and webcast details.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expected revenue for the third quarter of 2017, the amount of recording of additional revenue from backlog, the timing of reporting of third quarter financial results, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 1, 2017 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Doug Sherk, 646-445-4800
dsherk@evcgroup.com

Read More